Although Boston Scientific Corp (NYSE:BSX) reported fourth-quarter revenue and earnings ahead of consensus estimates, it announced disappointing 2026 guidance, according to Needham.
The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97.
The Boston Scientific Thesis: The company reported revenue of $5.286 billion and adjusted earnings of 80 cents per share, topping consensus estimates of $5.280 billion and 78 cents per share, respectively, Matson said in the note.
Check out other analyst stock ratings.
Boston Scientific’s organic growth slowed to 12.7%, from 15.3% in the third …